UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF THE
SECURITIES EXCHANGE ACT OF 1934
February
22, 2010
Date of
Report (Date of earliest event reported)
ELITE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-15697
|
|
22-3542636
|
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
165
Ludlow Avenue, Northvale, New Jersey 07647
(Address
of principal executive offices)
(201)
750-2646
(Registrant’s telephone number,
including area code)
|
|
|
(Former
name or former address, if changed since last
report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02. Results of Operations and Financial Condition.
The
information in this Item is furnished to, but not filed with, the Securities and
Exchange Commission (the “Commission”) solely under Item 12 of Form 8-K,
“Results of Operations and Financial Condition.”
On
February 22, 2010 Elite Pharmaceuticals, Inc. issued a press release that
included financial information for the three and nine months ended December 31,
2009. A copy of the press release is furnished as Exhibit 99.1 to this report
and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits
99.1
Press Release dated February 22, 2010.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
February 23, 2010
|
ELITE
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Chris Dick
|
|
|
Name:
Chris Dick
|
|
Title:
|
President
& Chief Operating
Officer
|